In this study, coatings of cross-linked gold nanoparticles (AuNPs) on flexible polyethylene (PE) substrates were prepared via layer-by-layer deposition and their application as strain gauges and chemiresistors was investigated. Special emphasis was placed on characterizing the influence of strain on the chemiresistive responses. The coatings were deposited using amine stabilized AuNPs (4 and 9 nm diameter) and 1,9-nonanedithiol (NDT) or pentaerythritol tetrakis(3-mercaptopropionate) (PTM) as cross-linkers. To prepare films with homogeneous optical appearance, it was necessary to treat the substrates with oxygen plasma directly before film assembly. SEM images revealed film thicknesses between ∼60 and ∼90 nm and a porous nanoscale morphology. All films showed ohmic I-V characteristics with conductivities ranging from 1 × 10⁻⁴ to 1 × 10⁻² Ω⁻¹ cm⁻¹, depending on the structure of the linker and the nanoparticle size. When up to 3% strain was induced their resistance increased linearly and reversibly (gauge factors: ∼20). A comparative SEM investigation indicated that the stress induced formation and extension of nanocracks are important components of the signal transduction mechanism. Further, all films responded with a reversible increase in resistance when dosed with toluene, 4-methyl-2-pentanone, 1-propanol or water vapor (concentrations: 50-10 000 ppm). Films deposited onto high density PE substrates showed much faster response-recovery dynamics than films deposited onto low density PE. The chemical selectivity of the coatings was controlled by the chemical nature of the cross-linkers, with the highest sensitivities (∼1 × 10⁻⁵ ppm⁻¹) measured with analytes of matching solubility. The response isotherms of all film/vapor pairs could be fitted using a Langmuir-Henry model suggesting selective and bulk sorption. Under tensile stress (1% strain) all chemiresistors showed a reversible increase in their response amplitudes (∼30%), regardless of the analytes' permittivity. Taking into consideration the thermally activated tunneling model for charge transport, this behavior was assigned to stress induced formation of nanocracks, which enhance the films' ability to swell in lateral direction during analyte sorption.

Efavirenz, the FDA-approved anti-retroviral medication, is evaluated in the clinical trial in patients with mild cognitive impairment or early dementia due to Alzheimer's disease. Efavirenz is assessed for activation of cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme that converts cholesterol to 24-hydroxycholesterol. Cholesterol 24-hydroxylation is the major pathway for brain cholesterol removal, and a mechanism that controls brain cholesterol turnover. The present study tested efavirenz on 5XFAD mice (an Alzheimer's model) at a very low daily dose of 0.1 mg/kg body weight. Efavirenz treatment started from three months of age, after amyloid plague appearance, and continued for 6 months. This treatment led to CYP46A1 activation in the brain, enhancement of brain cholesterol turnover, behavioral improvements, reduction in microglia activation but increased astrocyte reactivity. The levels of the soluble and insoluble amyloid 40 and 42 peptides were unchanged while the number and area of the dense core amyloid plaques were slightly decreased. The measurements of the brain levels of several pre-and post-synaptic proteins (Munc13-1, PSD-95, gephyrin, synaptophysin, synapsin-1, and calbindin-D28k) suggested efavirenz effect at the synaptic level. Efavirenz treatment in the present work seems to represent a model of behavioral and other improvements independent of the levels of the amyloid peptides and provides insight into potential outcomes of the future clinical trial.

A new, extremely efficient method for the fabrication of films comprised of gold nanoparticles (GNPs) crosslinked by organic dithiols is presented in this paper. The method is based on layer-by-layer spin-coating of both components, GNPs and crosslinker, and enables the deposition of films several tens of nanometers in thickness within a few minutes. X-ray diffraction and conductance measurements reveal the proper adjustment concentration of the crosslinker solution of the critical is in order to prevent the destabilization and coalescence of particles. UV/vis spectroscopy, atomic force microscopy, and conductivity measurements indicate that films prepared via layer-by-layer spin-coating are of comparable quality to coatings prepared via laborious layer-by-layer self-assembly using immersion baths. Because spin-coated films are not bound chemically to the substrate, they can be lifted-off by alkaline underetching and transferred onto 3d-electrodes to produce electrically addressable, freely suspended films. Comparative measurements of the sheet resistances indicate that the transfer process does not compromise the film quality.

Cholesterol is an important constituent of cell membranes and plays a crucial role in the compartmentalization of the plasma membrane and signaling. Brain cholesterol accounts for a large proportion of the body’s total cholesterol, existing in two pools: the plasma membranes of neurons and glial cells and the myelin membranes . Cholesterol has been recently shown to be important for synaptic transmission, and a link between cholesterol metabolism defects and neurodegenerative disorders is now recognized. Many neurodegenerative diseases are characterized by impaired cholesterol turnover in the brain. However, at which stage the cholesterol biosynthetic pathway is perturbed and how this contributes to pathogenesis remains unknown. Cognitive deficits and neurodegeneration may be associated with impaired synaptic transduction. Defects in cholesterol biosynthesis can trigger dysfunction of synaptic transmission. In this review, an overview of cholesterol turnover under physiological and pathological conditions is presented (Huntington’s, Niemann-Pick type C diseases, Smith-Lemli-Opitz syndrome). We will discuss possible mechanisms by which cholesterol content in the plasma membrane influences synaptic processes. Changes in cholesterol metabolism in Alzheimer’s disease, Parkinson’s disease, and autistic disorders are beyond the scope of this review and will be summarized in our next paper.